Johnson & Johnson (JNJ) Non-Current Deffered Revenue (2009)
Johnson & Johnson's (JNJ) quarterly Non-Current Deffered Revenue came in at $7.1 billion in Q3 2009, down 3.51% quarter-over-quarter from $7.4 billion in Q2 2009.
Johnson & Johnson (JNJ) Non-Current Deffered Revenue (2009) Analysis & Trends
Johnson & Johnson has disclosed Non-Current Deffered Revenue across 1 years of filings, most recently posting $7.1 billion for Q3 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | - |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | - |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | - |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 27, 2009 | 7.11 Bn |
| Jun 28, 2009 | 7.37 Bn |